Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir | Zendy

Wendy Ankrom | Zendy; Rosa I. Sánchez | Zendy; Ka Lai Yee | Zendy; Fan Li | Zendy; Pranab K. Mitra | Zendy; Dennis Wolford | Zendy; Ilias Triantafyllou | Zendy; Laura M. Sterling | Zendy; S. Aubrey Stoch | Zendy; Marian Iwamoto | Zendy; Sauzanne Khalilieh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir

Author(s) -

Wendy Ankrom,

Rosa I. Sánchez,

Ka Lai Yee,

Fan Li,

Pranab K. Mitra,

Dennis Wolford,

Ilias Triantafyllou,

Laura M. Sterling,

S. Aubrey Stoch,

Marian Iwamoto,

Sauzanne Khalilieh

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02491-18

Subject(s) - ledipasvir , pharmacology , pharmacokinetics , drug interaction , medicine , cmax , hepatitis c virus , virology , ribavirin , virus

Doravirine is a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Due to the high prevalence of HIV-1 and hepatitis C virus (HCV) coinfection and coadministration of HIV-1 and HCV treatment, potential drug-drug interactions (DDIs) between doravirine and two HCV treatments were investigated in two phase 1 drug interaction trials in healthy participants.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research